Market revenue in 2023 | USD 714.8 million |
Market revenue in 2030 | USD 1,013.9 million |
Growth rate | 5.1% (CAGR from 2023 to 2030) |
Largest segment | Pill |
Fastest growing segment | IUD |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pill, IUD, Injectable, Vaginal Ring, Implant, Patch |
Key market players worldwide | AbbVie Inc, Teva Pharmaceutical Industries Ltd, Bayer AG, Organon & Co Ordinary Shares, Pfizer Inc, Agile Therapeutics Inc, Johnson & Johnson, Lupin, Pregna International, Afaxys |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormonal contraceptive market will help companies and investors design strategic landscapes.
Pill was the largest segment with a revenue share of 57.6% in 2023. Horizon Databook has segmented the Canada hormonal contraceptive market based on pill, iud, injectable, vaginal ring, implant, patch covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada hormonal contraceptive market , including forecasts for subscribers. This country databook contains high-level insights into Canada hormonal contraceptive market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account